In terms of insulin for the treatment of T2DM, a study by Haider showed that insulin or somatostatin infusion suppressed glucose-induced elevation of visfatin (a novel insulin-mimetic adipocytokine) (28), which can reduce fat accumulation and insulin resistance in patients with T2DM. This evidence concerns the gene SST and Insulin resistance.